Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2026-03-26 @ 3:17 PM
Ignite Modification Date:
2026-03-26 @ 3:17 PM
NCT ID:
NCT07404969
Eligibility Criteria:
Inclusion Criteria:
* Biological female participants aged 25 to 42 years.
* Diagnosis of infertility defined as failure to conceive after at least 12 months of unprotected intercourse and/or repeated failure of assisted reproductive technologies (ART), including intrauterine insemination (IUI) and/or in vitro fertilization (IVF).
* History of post-treatment unexplained or functionally idiopathic infertility, defined as persistent infertility despite adequate correction or management of identifiable reproductive conditions (e.g., endometriosis, polycystic ovary syndrome, hormonal imbalance, uterine factors).
* Eligibility for natural conception attempts and/or assisted reproductive technologies according to routine clinical practice.
* Willingness to undergo biological aging biomarker profiling, including leukocyte telomere analysis.
* Ability and willingness to comply with study procedures, including the preconception integrative intervention and follow-up assessments.
* Provision of written informed consent prior to participation.
Exclusion Criteria:
* Current pregnancy or breastfeeding at the time of enrollment.
* Known chromosomal abnormalities or genetic conditions directly impairing fertility (e.g., Turner syndrome).
* Untreated severe male factor infertility precluding conception by natural or standard ART methods.
* Active malignancy or history of cancer requiring systemic treatment within the past 5 years.
* Severe systemic disease or medical condition contraindicating pregnancy or participation in ART (as determined by the treating physician).
* Use of investigational drugs or participation in another interventional clinical trial that could interfere with the study outcomes.
* Known hypersensitivity or contraindication to components of the integrative intervention, as determined by clinical assessment.
* Any condition which, in the opinion of the investigator, would interfere with safe participation or interpretation of study results.
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
25 Years
Maximum Age:
42 Years
Study:
NCT07404969
Study Brief:
Protocol Section:
NCT07404969